Drug intelligence / Profile preview

armodafinil + minocycline

Development stage: Unknown
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules
Administration: Oral

Overview

Armodafinil is a wakefulness-promoting agent used to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder. It is the R-enantiomer of modafinil. Minocycline is a second-generation tetracycline antibiotic with anti-inflammatory and neuroprotective properties, used for bacterial infections and investigated for neuropsychiatric disorders. The combination of armodafinil and minocycline has not been established as a standard therapy but may be considered in research contexts for potential synergistic effects on cognition or neuroprotection.

Other names: armodafinil and minocyclinearmodafinil/minocycline

Targets

Bacterial RibosomeDAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on armodafinil + minocycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on armodafinil + minocycline.

Explore the full profile